Clinical trials: Chronic Obstructive Pulmonary Disease, Unspecified
- Condition Chronic Obstructive Pulmonary Disease, Unspecified
- Funder type Industry (pharma, biotech, devices)
COPD
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen
The main goal of this study is to evaluate the efficacy and safety of glycopyrronium bromide and indacaterol maleate and glycopyrronium bromide fixed dose combination (FDC) in patients with moderate COPD who switch from their…
- Trial name
- NCT01985334
- Testing
- Glycopyrronium, SABA, LABA
- Where
- 542 sites in Austria, Belgium and 21 more
- Volunteers
- 4,389 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Observational Non-Interventional Study With Spiriva Respimat in COPD Patients
This observational non-interventional study is designed to demonstrate the improvement of physical function in COPD patients on treatment with Spiriva Respimat and allows adverse events to be recorded and evaluated.
- Trial name
- NCT00699699
- Where
- 188 sites in Germany
- Volunteers
- 1,280 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Cross Sectional Disease/Condition Focused Observational Study on Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to establish the prevalence of comorbidities in Italian patients with chronic bronchitis with at least 2 exacerbations per year, and to document the appropriateness of instrumental diagnostic tests…
- Trial name
- PREFER (NCT02100332)
- Where
- Italy
- Volunteers
- 860 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, COPD
Nasal High Flow Therapy 30 Day Readmission Study
The aim of this feasibility study is to provide data for a subsequent randomized controlled trial to investigate if patient outcomes will be improved after an acute COPD exacerbation using domiciliary nasal high flow therapy…
- Trial name
- N3ADS (NCT02552732)
- Testing
- NHF with or without Oxygen
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 29 people
- Sponsor
- Fisher and Paykel Healthcare
Chronic Obstructive Pulmonary Disease
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD
The purpose of this study is to compare Symbicort in a pressurized metered-dose inhaler (pMDI) with formoterol and placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00206167
- Testing
- Budesonide/formoterol pMDI, Formoterol Turbuhaler
- Where
- 216 sites in United States, Bulgaria and 7 more
- Volunteers
- 1,600 people
- Sponsor
- AstraZeneca
Moderate to Severe COPD
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD.
- Trial name
- INDOS-B (NCT06531798)
- Testing
- Breztri Aerosphere
- Where
- 6 sites in India
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD) Breathing Record Study
This study is being done to collect information that will be used in the development of a new medical device. The new device is intended to help people with COPD to monitor their condition at home on a daily basis.
- Trial name
- CBRS (NCT02814253)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- TidalSense
Chronic Obstructive Pulmonary Disease
CareCOPD - COPD Home Monitoring Study
This is a pilot study to demonstrate early validation of objective home-monitoring of Chronic obstructive pulmonary disease (COPD) patients by combining accurate and relevant patient data of medication and lung function (lung…
- Trial name
- NCT04918095
- Testing
- CareCOPD Platform
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cognita Labs LLC
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease…
- Trial name
- INTRUST2 (NCT00877383)
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 176 sites in United States, Canada and 7 more
- Volunteers
- 1,142 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Study in Patients With Chronic Obstructive Pulmonary Disease
The primary objective of the study was to demonstrate the superiority of Foster® 100/6 (two puffs b.i.d.) versus Seretide® 500/50 (one inhalation b.i.d.), in terms of pulmonary function (AUC0-30min standardized by time of change…
- Trial name
- FUTURE (NCT01245569)
- Testing
- Beclomethasone Dipropionate - Formoterol, Fluticasone - Salmeterol
- Where
- 68 sites in Denmark, France and 8 more
- Volunteers
- 419 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol
This study investigated the effect of exercise and high-dose salbutamol on the maximum heart rate in patients with chronic obstructive pulmonary disease (COPD) receiving therapeutic doses of indacaterol, salmeterol and placebo.
- Trial name
- NCT00531050
- Testing
- Indacaterol, Salmeterol
- Where
- Belgium
- Volunteers
- 27 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease (COPD)
Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD
The study was designed to investigate the efficacy and safety of different doses CHF5259 a long acting muscarinic antagonist in patients with moderate to severe COPD.
- Trial name
- GlycoNEXT (NCT02680197)
- Where
- 30 sites in Czechia, Germany and 2 more
- Volunteers
- 262 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to determine whether inhalation of Bimosiamose is safe and effective in the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01108913
- Testing
- Bimosiamose
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Revotar Biopharmaceuticals AG
Pulmonary Disease, Chronic Obstructive
12 / 48 Week Pivotal PFT vs PBO in COPD I
This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00782210
- Testing
- Olodaterol (BI1744)
- Where
- 54 sites in United States, Australia and 4 more
- Volunteers
- 625 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers
The primary objective of this study is to evaluate the efficacy and safety of orally inhaled tiotropium and olodaterol as both a fixed dose combination and a free combination with respect to lung function and ECG parameters
- Trial name
- NCT02030535
- Testing
- olodaterol, tiotropium
- Where
- 6 sites in Germany
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to determine if tiotropium (Spiriva, Bromuro de Tiotropio) 18 mcg once daily by oral inhalation compared to placebo increases the magnitude of daily physical activity observed in COPD patients…
- Trial name
- NCT00144326
- Testing
- Tiotropium Bromide
- Where
- 27 sites in Canada, Germany and 1 more
- Volunteers
- 250 people
- Sponsor
- Boehringer Ingelheim
COPD
Continuous Monitoring of Patients With Chronic Obstructive Pulmonary Disease
An open, single group, single center Study to confirm CTC-Actiwise™ as a means to record and monitor the progression of a patient's COPD. Chronic Obstructive Pulmonary Disease (COPD) affects growing patient groups.
- Trial name
- CTC-Actiwise (NCT01741935)
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- CareTelCom AB
Chronic Obstructive Pulmonary Disease
Evaluation of Clinical Effectiveness of Roflumilast in Routine Practice, in Chronic Obstructive Pulmonary Disease (COPD) Patients in Greece
The purpose of this study was to examine the characteristics of patients selected for treatment with roflumilast and the effectiveness and safety of roflumilast in patients with severe or very severe COPD treated in Hospital and…
- Trial name
- ATLAS (NCT02187926)
- Volunteers
- 2,577 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects
A study to assess the pharmacokinetics and safety of two doses of PT010 and a single dose of PT003 in healthy Chinese adult subjects
- Trial name
- NCT03075267
- Testing
- PT010 (BGF MDI) 320/14.4/9.6 µg, PT010 (BGF MDI) 160/14.4/9.6 µg, PT003 (GFF MDI) 14.4/9.6 µg
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
- Trial name
- PRESTO (NCT07082738)
- Testing
- AZD6793
- Where
- 367 sites in United States, Argentina and 22 more
- Volunteers
- 987 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.